Is CTX.TO undervalued or overvalued?

As of 2025-03-17, the Intrinsic Value of Crescita Therapeutics Inc (CTX.TO) is 0.09 CAD. This CTX.TO valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 0.51 CAD, the upside of Crescita Therapeutics Inc is -82.60%. This means that CTX.TO is overvalued by 82.60%.

The range of the Intrinsic Value is 0.12 - (0.09) CAD

	Range	Selected	Upside
a
DCF (Growth 5y)	(5.40) - (0.51)	(1.12)	-319.5%
DCF (Growth 10y)	(0.53) - (4.92)	(1.07)	-310.6%
DCF (EBITDA 5y)	0.12 - (0.09)	0.09	-82.6%
DCF (EBITDA 10y)	0.03 - 0.00	0.01	-98.0%
Fair Value	-0.72 - -0.72	-0.72	-240.91%
P/E	(0.56) - (0.61)	(0.56)	-209.9%
EV/EBITDA	0.10 - (0.59)	0.09	-81.6%
EPV	1.87 - 2.51	2.19	329.6%
DDM - Stable	(1.81) - (16.01)	(8.91)	-1846.7%
DDM - Multi	(0.12) - (0.82)	(0.21)	-140.8%